ESMO 2026 Exhibitors
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
235 organizations exhibit at ESMO 2026 — 145 industry and service companies, 74 drug developers, 13 societies and non-profits and 3 cancer centres and hospitals. 38 of them also present on the scientific program, with 112 presentations between them. Most represented: MD Anderson Cancer Center (21 on the program), Institut Curie (5 on the program), City of Hope (3 on the program). 235 of them have their own page in this guide. As of Sep 29, 2026.
Tumour type
Top represented
Showing 1–30 of 235 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, TX | |
Comprehensive cancer treatment and research centre of the University of Texas in Houston, Texas. | Booth Exhibiting at Booth 8006 Talk Fri Oct 23 13:30 Talk Fri Oct 23 14:30–14:45 Chair Fri Oct 23 16:15–17:45 Emerging therapeutic strategies in advanced prostate cancer Genitourinary cancers Abstract Fri Oct 23 16:47–16:52 Talk Fri Oct 23 17:15–17:35 New targets (ADCs, new biologies) Genitourinary cancers Satellite Fri Oct 23 18:45–19:10 Elacestrant in ESR1-mutant mBC: Establishing the Standard of Care Breast cancerBiomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Abstract Sat Oct 24 08:35–08:40 Abstract Sat Oct 24 08:45–09:00 Invited Discussant LBA73, 2719RO and 2700RO Lung & thoracic cancers Talk Sat Oct 24 09:10–09:30 Satellite Sat Oct 24 13:05–13:25 KRAS G12C Biology: A Unique Oncogenic Driver With Dual Impact Lung & thoracic cancers Satellite Sat Oct 24 14:00–14:15 A new chapter? The evolving role of ADCs in mCRC Gastrointestinal cancers Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 15:05–15:15 Abstract Sat Oct 24 15:15–15:27 Chair Sat Oct 24 16:30–18:00 Updates on myeloid neoplasms with a focus on medical oncology practice Haematological malignancies Talk Sat Oct 24 17:10–17:30 Current treatment landscape of AML based on a comprehensive genomic assessment Haematological malignancies Abstract Sun Oct 25 08:30–08:35 Abstract Sun Oct 25 08:30–08:35 4244RO - NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase 2 perioperative trial Biomarkers & precision oncology Abstract Sun Oct 25 09:19–09:24 Talk Sun Oct 25 10:45–11:00 Satellite Sun Oct 25 13:10–13:25 Emerging evidence in BRAFV600E-mutant mCRC Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 15:15–15:25 Talk Sun Oct 25 15:30–15:50 Pathological response for the win Melanoma & skin cancers Abstract Sun Oct 25 16:30–16:42 LBA5 - Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC Lung & thoracic cancersGastrointestinal cancers Chair Sun Oct 25 16:30–18:00 Rapid oral: Supportive and palliative care Nursing & supportive care Abstract Sun Oct 25 16:45–16:55 Invited Discussant 3469RO, 3085RO and 3895RO Nursing & supportive care Chair Mon Oct 26 08:30–10:00 Chair Mon Oct 26 08:30–10:00 Talk Mon Oct 26 09:15–09:30 Abstract Mon Oct 26 09:22–09:37 Talk Mon Oct 26 10:35–10:55 Biology and mechanisms of action of novel immunotherapies Lung & thoracic cancers Satellite Mon Oct 26 13:05–13:25 Charting the Path Forward in KRAS G12C Lung Cancer Lung & thoracic cancers Talk Mon Oct 26 14:45–15:00 Chair Mon Oct 26 14:45–16:15 Chair Mon Oct 26 14:45–16:15 Abstract Mon Oct 26 15:44–15:49 Abstract Mon Oct 26 15:49–15:59 Talk Mon Oct 26 16:30–16:45 IO-based systemic therapy (incl pt selection) Sarcoma, CNS, head & neck and rare cancers Satellite Mon Oct 26 19:25–19:50 Managing Complexity: Sequencing HER2-Directed Therapies After Progression Lung & thoracic cancersBiomarkers & precision oncology |
Institut Curie Paris, France | |
Private non-profit cancer centre in Paris, France, combining a research centre with hospital sites. | Booth Exhibiting at Booth 8042 Satellite Fri Oct 23 09:50–10:15 Satellite Fri Oct 23 18:15–19:45 Satellite Fri Oct 23 18:15–18:20 Welcome Melanoma & skin cancers Satellite Fri Oct 23 19:15–19:40 Interactive Case and Panel Discussion: Applying Evidence to Practice Melanoma & skin cancers Satellite Sat Oct 24 13:05–13:35 Maximizing 1L outcomes in HR+ mBC Breast cancer Talk Sat Oct 24 17:00–17:15 How to monitor biomarkers and ctDNA Breast cancerBiomarkers & precision oncology Satellite Sun Oct 25 13:20–14:05 Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate Lung & thoracic cancers Satellite Sun Oct 25 14:05–14:25 Looking To the Future: How Emerging Strategies Could Address Unmet Needs in NSCLC Lung & thoracic cancers Talk Sun Oct 25 15:25–15:45 Toxicities of cytokines and intratumoral immunotherapies Nursing & supportive care Chair Sun Oct 25 18:30–20:00 Talk Sun Oct 25 19:25–19:45 Ongoing research and horizon scanning in cancer with ROS1 rearrangements Lung & thoracic cancers Talk Mon Oct 26 09:30–09:50 |
City of Hope Duarte, CA | |
Independent cancer research and treatment organization based in Duarte, California, with an NCI-designated comprehensive cancer centre and sites across the US. | Booth Exhibiting at Booth 8038 Abstract Sat Oct 24 08:30–08:40 Satellite Sat Oct 24 12:00–13:30 Satellite Sat Oct 24 12:00–12:10 Opening: Why Subcutaneous Immunotherapy Now? A Nurse Led Lens Nursing & supportive care Satellite Sat Oct 24 12:50–13:25 Satellite Sat Oct 24 13:25–13:30 Conclusion remarks Nursing & supportive care Satellite Sat Oct 24 18:43–19:23 Navigating the RCC treatment journey Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 09:22–09:32 Talk Sun Oct 25 10:30–11:15 Talk Sun Oct 25 15:00–15:15 Talk Mon Oct 26 16:00–16:05 |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan. | Booth Exhibiting at Booth 8066 Talk Fri Oct 23 13:30 Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 10:15–11:45 AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Mon Oct 26 13:00–14:30 AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer Gastrointestinal cancers |
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib. | Booth Exhibiting at Booth 1023 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 13:00–14:30 GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care Gynaecological cancers Talk Mon Oct 26 10:55–11:15 |
German Breast Group (GBG) Neu-Isenburg, Germany | |
German academic research organisation that designs and runs clinical trials in breast cancer. | Booth Exhibiting at Booth 1095 Chair Sun Oct 25 10:15–11:45 Optimising treatment for HER2+ early breast cancer Breast cancer Talk Sun Oct 25 11:15–11:35 What to do after optimal neoadjuvant therapy? Breast cancer |
European Organisation for Research and Treatment of Cancer (EORTC) Brussels, Belgium | |
Independent non-profit that runs international academic cancer clinical trials across Europe. | Booth Exhibiting at Booth S1041 Abstract Sat Oct 24 15:47–15:52 |
Global contract research and healthcare data company providing clinical trial services and real-world evidence. | Booth Exhibiting at Booth 1001 Satellite Sun Oct 25 19:35–19:55 How Do Patient-Reported Outcomes Influence Reimbursement Decisions? Nursing & supportive care |
Global pharmaceutical company, known as Merck & Co. in the US and Canada, whose oncology medicines include pembrolizumab. | Booth Exhibiting at Booth 8030 Satellite Fri Oct 23 09:45–11:15 MSD - Emerging Evidence and Treatment Integration in Ovarian and Endometrial Cancer Gynaecological cancersBiomarkers & precision oncology Satellite Sat Oct 24 12:00–13:30 Satellite Sat Oct 24 13:00–14:30 MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC Sarcoma, CNS, head & neck and rare cancers Satellite Sun Oct 25 18:30–20:00 MSD - Is the precision medicine ecosystem ready? Overcoming diagnostic barriers in oncology Biomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers Satellite Mon Oct 26 13:00–14:30 |
Daiichi Sankyo Tokyo, Japan | |
Japanese pharmaceutical company developing antibody-drug conjugates including trastuzumab deruxtecan and datopotamab deruxtecan. | Booth Exhibiting at Booth 8033 Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Sun Oct 25 18:30–20:00 Daiichi Sankyo - Patient Identification in NSCLC: 10 From Actionable Genomic Alterations to Emerging ADC Opportunities Lung & thoracic cancersBiomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers |
Global pharmaceutical company whose oncology medicines include abemaciclib, selpercatinib and pirtobrutinib. | Booth Exhibiting at Booth 1058 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 18:30–20:00 Satellite Sun Oct 25 13:15–14:45 |
Healthcare company whose Innovative Medicine business markets oncology drugs including amivantamab, daratumumab and teclistamab. | Booth Exhibiting at Booth 1029 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 14:00–15:30 J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers |
WebMD's medical news and continuing-education service for physicians and other clinicians. | Booth Exhibiting at Booth 8072 Satellite Fri Oct 23 09:45–11:15 Satellite Sat Oct 24 18:30–20:00 Satellite Sun Oct 25 13:00–14:30 |
Global pharmaceutical company whose oncology portfolio spans breast, lung, prostate, bladder and blood cancers, including antibody-drug conjugates from its Seagen acquisition. | Booth Exhibiting at Booth 8031 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 18:30–20:00 Pfizer - Breaking the Treatment Plateau in Advanced NSCLC: Antibody Therapy Redefined Lung & thoracic cancers Satellite Sun Oct 25 18:30–20:00 |
US biotechnology company whose cancer medicines include the PD-1 antibody cemiplimab and bispecific antibodies for blood cancers. | Booth Exhibiting at Booth 1017 Satellite Sun Oct 25 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Satellite Sun Oct 25 18:30–20:00 Regeneron - Perspectives on Early-stage Melanoma: Diagnosis, Staging, and Treatment Melanoma & skin cancers |
Swiss healthcare company with a large portfolio of cancer medicines and diagnostics, including antibodies, antibody-drug conjugates and tissue and molecular tests. | Booth Exhibiting at Booth 1030 Satellite Fri Oct 23 18:15–19:45 Satellite Sun Oct 25 13:00–14:30 Satellite Mon Oct 26 13:00–14:30 F. Hoffmann - La Roche LTD - Advancing the Frontiers of Lung Cancer Care Lung & thoracic cancers |
Astellas Tokyo, Japan | |
Japanese pharmaceutical company whose oncology medicines include enzalutamide, enfortumab vedotin and zolbetuximab. | Booth Exhibiting at Booth 1054 Satellite Fri Oct 23 18:15–19:45 Astellas - Solving the puzzle: Optimising practice in CLDN18.2+ gastric/GEJ adenocarcinoma Gastrointestinal cancers Satellite Sun Oct 25 13:00–14:30 |
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company whose oncology medicines include nivolumab, ipilimumab and nivolumab plus relatlimab. | Booth Exhibiting at Booth 8069 Satellite Fri Oct 23 09:45–11:15 Satellite Sat Oct 24 13:00–14:30 |
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies. | Booth Exhibiting at Booth 8063 Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers |
German science and technology company whose healthcare business markets oncology medicines including avelumab, cetuximab and tepotinib. | Booth Exhibiting at Booth 1034 Satellite Sat Oct 24 13:00–14:30 Merck Healthcare KGaA - Striving for more: The cutting edge of therapeutic developments in mCRC Gastrointestinal cancers Satellite Mon Oct 26 13:00–14:30 Merck Healthcare KGaA - CARE FOR RARE: Desmoid Tumours in Clinical Practice − Shifting Strategies & Evolving Perspectives Sarcoma, CNS, head & neck and rare cancers |
Swiss pharmaceutical company whose oncology medicines include ribociclib for breast cancer and radioligand therapies. | Booth Exhibiting at Booth 1059 Satellite Sat Oct 24 13:00–14:30 Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future Genitourinary cancers Satellite Mon Oct 26 13:00–14:30 |
French pharmaceutical group whose oncology medicines include vorasidenib for IDH-mutant glioma and treatments for colorectal and pancreatic cancer and leukaemia. | Booth Exhibiting at Booth 8064 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 13:00–14:30 Servier - GI Oncology in Motion : Real-World Cases and Patient Centric Care Gastrointestinal cancersBiomarkers & precision oncology |
Abbott Abbott Park, IL | |
Global healthcare company making diagnostics, medical devices and nutrition products; now owns Exact Sciences' cancer testing business. | Booth Exhibiting at Booth 8071 Satellite Mon Oct 26 13:00–14:30 |
AbbVie North Chicago, IL | |
Global biopharmaceutical company with oncology medicines including venetoclax, ibrutinib and antibody-drug conjugates. | Booth Exhibiting at Booth 8034 Satellite Fri Oct 23 09:45–11:15 AbbVie - Riding the Wave of Innovation Towards Personalized Medicine in Ovarian Cancer Gynaecological cancers |
Generic and biosimilar medicines company, part of India's Intas Pharmaceuticals, with a large oncology portfolio. | Booth Exhibiting at Booth 1018 Satellite Mon Oct 26 18:30–20:00 Accord Healthcare - Navigating immunotherapy options in first-line ES-SCLC and NSCLC Lung & thoracic cancers |
Bayer Leverkusen, Germany | |
German life-sciences company whose oncology medicines include darolutamide, regorafenib and radium-223. | Booth Exhibiting at Booth 1046 Satellite Sat Oct 24 12:00–13:00 Bayer - Recognising and Managing the invisible Symptoms: The Critical Role of the Oncology Nurse Nursing & supportive careBreast cancer |
Global oncology company, formerly BeiGene, marketing zanubrutinib and tislelizumab. | Booth Exhibiting at Booth 8026 Satellite Sun Oct 25 13:00–14:30 |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned German pharmaceutical company developing oncology drugs such as zongertinib for HER2-mutant lung cancer. | Booth Exhibiting at Booth 1065 Satellite Sat Oct 24 18:30–20:00 |
Eisai Tokyo, Japan | |
Japanese pharmaceutical company whose oncology medicines include lenvatinib and eribulin. | Booth Exhibiting at Booth 8067 Satellite Fri Oct 23 09:45–11:15 Eisai - RCC in Motion: First-Line Choice and the Evolving RCC Treatment Landscape Genitourinary cancers |
Vietnam-based genomic testing company offering multi-cancer early detection, liquid biopsy and genetic tests. | Booth Exhibiting at Booth 8060 Satellite Fri Oct 23 09:45–11:15 |
Instantly find 20 buyers from ESMO 2026 exhibitors
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
- Exhibitors 235
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction